Expand ARQT Menu
ARQT MENU

ARQT Latest Press Releases

-- August 7, 2026 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- August 5, 2026 --

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:00 PM

-- July 16, 2026 --

Arcutis Expands Board of Directors with Appointment of Chris Peetz Globe Newswire 9:00 AM

-- July 15, 2026 --

Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 Globe Newswire 4:00 PM
Attovia Therapeutics Appoints John W. Smither to Board of Directors Globe Newswire 8:30 AM

-- July 8, 2026 --

FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months Globe Newswire 8:00 AM

-- July 2, 2026 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- June 30, 2026 --

Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE (roflumilast) Indications Globe Newswire 9:15 AM

-- June 29, 2026 --

FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2 Globe Newswire 7:06 PM

-- June 5, 2026 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- June 3, 2026 --

New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology Globe Newswire 8:00 AM

-- May 26, 2026 --

Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference Globe Newswire 4:00 PM

-- May 8, 2026 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- May 6, 2026 --

Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:00 PM

-- April 27, 2026 --

Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months Globe Newswire 8:00 AM

-- April 22, 2026 --

Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines Globe Newswire 8:00 AM

-- April 15, 2026 --

Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 Globe Newswire 4:00 PM

-- April 8, 2026 --

The Credibility Filter Wall Street Uses to Sort Biotech Winners Globe Newswire 9:15 AM

-- April 7, 2026 --

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales Globe Newswire 7:30 AM

-- March 31, 2026 --

Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference Globe Newswire 4:00 PM

-- March 28, 2026 --

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting Globe Newswire 11:00 AM

-- March 18, 2026 --

Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting Globe Newswire 8:00 AM

-- March 10, 2026 --

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2-5 in Pediatric Dermatology Globe Newswire 9:00 AM
Market Data Delayed 15 Minutes